The 10th Annual C21 BioVentures Presenter Profiles

NAPA, Calif.--(BUSINESS WIRE)--10th Annual C21 BioVentures takes place May 20 - 22, 2008 at The Meritage Resort at Napa in Napa, CA. Listed below are the 10th Annual C21 BioVentures presenter profiles. For in-depth information about the event, visit http://www.techvision.com/c21/.

Business Wire is the official news wire for the 10th Annual C21 BioVentures conference. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Company:	ApopLogic Pharmaceuticals, LLC
Media Contact:	Dr. Richard C. Duke
Phone:	720-255-5722
E-mail:	richard.duke@apoplogic.com
Web:	www.apoplogic.com
ApopLogic Pharmaceuticals is a Colorado-based, oncology drug development company that was founded in 2006 by University of Colorado faculty Drs. Donald Bellgrau, Paul Bunn, Richard Duke, Daniel Chan, Lajos Gera, Jaime Modiano, and John Stewart. ApopLogic takes advantage of an understanding of the receptors and ligands that control natural cell death (apoptosis). Put most simply, ApopLogic helps cancer cells to commit suicide. Uniquely, these products also target inflammatory cells and factors in the tumor microenvironment that potentiate cancer cell growth and metastasis. The Company is planning initiation of clinical trials in lung, prostate and head and neck cancers in 2009.
Company:	Asphelia Pharmaceuticals, Inc
Phone:	858-731-8520
E-mail:	xfrapaise@aspheliapharma.com
Web:	www.aspheliapharma.com
San Diego-based Asphelia Pharmaceuticals is a fast-growing immunotherapeutic company focused on the development of therapies for Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) and other immunological and inflammatory disorders, including multiple sclerosis and asthma.
Our lead compounds target the cause of Inflammatory Bowel Disease, not just its symptoms, to change the course of the diseases and give patients new freedoms. We also have a unique topically administered therapy for allergic disorders that is currently in development.
We expect to enter Phase IIa clinical trials with all three of our programs in 2008.
Company:	Falco Biotherapeutics
Media Contact:	Michel Bergh PhD
Phone:	1-415-203-5041
E-mail:	bergh@falcobio.com
Web:	www.falcobio.com
Falco Biotherapeutics is a transatlantic biotech startup resulting from the merger between Farallone Therapeutics and Lactrys. This merger created the convergence of two independently proven technologies. On one hand, Falco has created a new generation of affinity proteins, named ElCams™, that have the same specificity as antibodies, but with some of the benefits of small molecules. On the other hand, Falco has developed a unique delivery technology based on the genetic modification of Lactobacillus. This enables us to deliver our ElCams™, following oral administration, entirely intact and fully functional, to the gastro-intestinal lumen, where they can absorb, neutralize and inactivate undesirable substances, such as bacterial toxins, inflammatory cytokines. We are pursuing two indications: CDAD (Clostridium difficile associated diarrhea) and inflammatory bowel disease.
Company:	ImmunoVaccine Technologies Inc.
Media Contact:	Jennifer Ayotte
Phone:	(902) 423-6610 ex 315
E-mail:	jayotte@impactcommunications.ca
Web:	www.immunovaccine.com
ImmunoVaccine Technologies Inc. (IVT) is a private clinical-stage biotechnology company developing infectious disease and therapeutic cancer vaccines for human health. IVT’s vaccines which use breakthrough VacciMax® and DepoVax™ enhancement and delivery platforms with validated antigens will position IVT as a key player in development of premium vaccine products. In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal Health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.
Company:	Maven Biotechnologies, LLC
Media Contact:	Jeffrey C. Travis, Ph.D.
Phone:	626-793-9870
E-mail:	jtravis@mavenbiotech.com
Web:	www.mavenbiotech.com
Maven Biotechnologies, LLC to Present at C21 BioVentures Investor Conference
Pasadena, Ca. – Maven Biotechnologies, an early stage biotechnology company developing a label-free multiplexing immunoassay analysis system, will deliver a presentation at the C21 BioVentures Investor Conference in Napa, California. Jeffrey C. Travis, Ph.D., Maven’s President and COO will present on Wednesday, May 21, 2008 at 2:45 PM. Maven Biotechnologies, LLC has developed LFIRE™ (Label-Free Internal Reflection Ellipsometry), a complete biomarker analysis system (instruments & disposables) that provides significant cost benefits (>50-90% reduced costs) to healthcare’s pharma and diagnostics sector. Market launch of first commercial products is planned for 2009.
Company:	OsteoCorp Inc.
Media Contact:	Tim Brons, Vida Communication
Phone:	415 675-7402
E-mail:	tbrons@vidallc.com
Web:	http://www.osteocorp.com
OsteoCorp is an emerging specialty pharmaceutical company developing proprietary, controlled-release formulations of its Osoprol™ beta-blocker to increase the density and quality of bone as a treatment for osteoporosis, skeletal fracture repair, implant fixation and other disorders. Osoprol represents a newly identified class of bone-forming drug that may be as good or better than Lilly’s Forteo (a parathyroid hormone analog), the only bone anabolic drug on the market today. Because OsteoCorp is “re-purposing” an existing FDA-approved beta-blocker, it will not require extensive R&D scale-up, and can cost-effectively out-source the bulk of its product development at a fraction of the time and cost of a typical new drug candidate.
Company:	Ribomed Biotechnologies, Inc.
Media Contact:	Dr. Michelle Hanna
Phone:	760-448-1355
E-mail:	mmh@ribomed.com
Web:	www.ribomed.com
Ribomed is developing tests for the early detection and characterization of diseases and the screening of drugs for treatment, particularly in the area of epigenetics. Ribomed has developed a robust, isothermal molecular detection process, Abscription, which is resistant to blood, saliva and most environmental substances that inhibit tests based on PCR. Abscription allows detection of multiple targets in a single sample and can be used for DNA, RNA, protein, or CpG methylation on a single device with a common set of reagents. Current tests under development are for disease associated changes in CpG methylation and mi-RNA levels.
Company:	Sidec AB
Phone:	+46 8 560 02 105
E-mail:	cecile.hakala@sidec.com
Web:	www.sidec.com
Sidec is the leading provider of three-dimensional (3D) images of individual proteins. Sidec’s proprietary technology; Protein Tomography™, enables a rapid localization of antibody binding epitopes and to validate molecular mode of action.
This allows our partners to protect intellectual property with visual evidence to develop better therapeutic antibodies faster.
At PEGS 2008 in Boston, Sidec announced the first Protein Tomography™ Award enabling research groups in the biopharmaceutical industry who have not yet worked with Sidec to get acquainted with Protein Tomography™.
The winning project will obtain a Protein Tomography™ collaboration.
Company:	Silamed, Inc.
Media Contact:	Craig Taylor
Phone:	(480) 268-2080
E-mail:	ctaylor@silamed.com
Web:	www.silamed.com
Silamed Inc. is a private, Arizona-based pharmaceutical company whose mission is to utilize its silicon medicinal chemistry platform to cost-effectively design and develop derivatives of existing drugs with enhanced clinical benefit and new intellectual property. Silamed’s lead program, Silexsyn (SiM-100) is a silicon-modified version of a well-known and approved non-steroidal anti-inflammatory drug (NSAID) indomethacin, a compound with demonstrated clinical activity in the treatment of cancer. Silexsyn has significantly increased COX-2 selectivity, compared to indomethacin, and has superior anticancer activity in preclinical models. Silamed plans to develop Silexsyn, in combination with chemotherapeutics, for the treatment of cancer.
Company:	VM Discovery, Inc.
Booth:	Table 17, May 22
Media Contact:	Jay Wu, Ph.D.
Phone:	1-510-818-1018
E-mail:	wu@vmdiscovery.com
Web:	www.vmdiscovery.com
VM Discovery, Inc. is a California biotech company focused on invention and commercialization of re-positioned marketed drugs and differentiated small-molecule drug candidates to treat pain and cancer. It has strong pipeline/solid IPs of drug candidates in development (e.g. T-type Calcium ion channel blockers, Bcl-2 and NGF/TrkA inhibitors), outstanding operation efficiency, proven high success-rate and fast cycle-time in inventing/developing optimized drug candidates with its disruptive product engine, the "VMOptimizer". Its business model is balanced between long-term high upside potential and short-term economic return, i.e. selectively clinical developing its repositioned marketed drugs, while out-licensing/partnering other novel drug candidates in early clinical or late preclinical stages.
Company:	Zymeworks Inc.
Media Contact:	Dr. David K. Y. Poon
Phone:	+1 (604) 678-1388 x133
E-mail:	dpoon@zymeworks.com
Web:	www.zymeworks.com
Zymeworks is a private company seeking to become the global leader in computational protein modeling and engineering of protein therapeutics and industrial enzymes.
Zymeworks has built a technology platform from the ground-up that combines proprietary molecular simulation software with high-performance computing to create a comprehensive environment for structure-based predictive protein optimization and design.
For antibodies and protein therapeutic candidates, stability, half-life, binding affinity, and immunogenicity can be successfully engineered. Likewise for industrial enzymes, stability, substrate specificity, enantioselectivity, and stereoselectivity, product inhibition, and solubility can be modulated.
Zymeworks is interested in forming strategic partnerships with industry leaders seeking to supplement their R&D with structure-based computational technologies.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow [at] businesswire.com.